New Zealand media is reporting current failure rates in the ASR metal-on-metal hips are nearly 25%. This rate has grown substantially from earlier reports, and it confirms rates in other countries. Approximately 60% of our clients have had revisions.
New Zealand and Britain were home to Johnson & Johnson subsidiaries which were able to make strong inroads into the hip implant business. Our firm has clients nominated to take part as lead trial plaintiffs. While final choices have not been made, our aggressiveness makes us privy to what is not always publically known. For instance, there appears to be major discrepancies in the knowledge shared between the British, New Zealand and United States Johnson & Johnson divisions. Our litigation drive is to find out what the company knew, when they knew it, and what they did with the information when they knew it.
Many newspapers as well as a prestigious British Medical journal have revealed that when Johnson & Johnson made the decision to stop selling the DePuy ASR hip implants in 2009 (after an FDA non-approval letter), they did NOT tell the public. And yet, at the same time, they continued to sell off the remaining stock of the implants-the ones they recalled in 2010. Company emails show internal debates about the dangers of metallosis and implant failure while publically promoting the devices.